A common flu virus could be used to overcome patients’ resistance to certain cancer drugs — and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London (QMUL).
The work, funded by UK charity Pancreatic Cancer Research Fund, contributes to a growing area in cancer treatment in which viruses are harnessed to kill cancer cells.
Viruses can be modified to specifically infect cancer cells, and use them as a factory to generate thousands of new viruses, replicating until the cancer cell bursts. The virus copies will then spread and infect surrounding tumour cells and repeat the process, leaving healthy cells unharmed.
But the body’s immune system will usually kill off the virus before it is able to infect all the cells within a tumour. In pancreatic cancer, therefore, drugs such as gemcitabine are currently the most common treatment — they work by damaging the DNA in the cancer cells, so they are unable to divide successfully. This damage triggers a process called apoptosis, in which damaged or unhealthy cells are forced to self-destruct.
Over time, however, the cancer cell becomes able to delay apoptosis in order to repair the damage to its DNA, which means that the cells survive and continue to divide and spread and the drug becomes less effective.
In a study published in the journal Oncotarget, the team at QMUL’s Barts Cancer Institute introduced a genetic modification to the virus, called adenovirus, to give it an extra weapon against cancer cells.
By switching off a particular gene in the virus which counteracts apoptosis, the scientists found cancer cells studied in the laboratory were unable to delay apoptosis and so forced to die without dividing. The modified virus still infects some cancer cells and replicates until the cell bursts, but by also preventing the cancer cells from developing drug resistance, it works with the anti-cancer drug to increase the number of cells that are killed.
“Many cancers — including pancreatic cancer — become resistant to treatments like gemcitabine, and currently there’s no way to get round that,” explains Dr Gunnel Halldèn, who led the research. “The virus that we have modified re-sensitises the resistant cancer cell by preventing the cell from repairing itself. The virus alone will kill some tumour cells, but in combination with the drug, the number of cells that are killed is greatly increased.
“Because the virus improves the efficacy of the drug, it means it could also be possible to give lower doses, which will also reduce the unpleasant side-effects associated with chemotherapy,” she adds.
Developing virus-based cancer therapies has been a key goal in cancer research for several years and some technologies have already moved into the clinic: last year, for example, a melanoma therapy, based on a herpes virus called T-VEC, was approved for use in the US and in Europe.
The QMUL research is at an early stage, but the team believe they have found a promising new route for developing combination treatments for pancreatic cancer.
The next step for the researchers will be to test other modified versions of adenovirus to better understand the exact mechanism through which it enhances cell killing. Further modifications will also be made to enable the virus to trigger the body’s immune system, which will attack any cancer cells that have not been infected by the virus.
The Latest on: Virus-based cancer therapies
via Google News
The Latest on: Virus-based cancer therapies
- Could the common cold 'revolutionize' bladder cancer treatment?on July 13, 2019 at 3:04 am
Current treatment for some forms of cancer does not work as well as researchers had initially hoped. But a new virus-based treatment has shown promising results. Using viruses to treat cancer has long ...
- News of Note—Merck's virus-based drug shows promise in bladder cancer; CRISPR halts hearing loss in miceon July 8, 2019 at 8:17 am
the team reported that Cavatak boosted cancer cell death in all of the 15 patients who received the treatment, and that in one patient, no trace of the cancer was found during surgery. (Release) A ...
- Bladder cancer 'attacked and killed by common cold virus'on July 4, 2019 at 5:08 pm
A strain of the common cold virus can infect and kill bladder cancer cells, a small study suggests. All signs of the disease disappeared in one patient, and in 14 others there was evidence that cancer ...
- Calidi Biotherapeutics Granted Patent for Cell-Based Oncolytic Virus Immunotherapy for Cancer Treatmenton May 7, 2019 at 1:01 pm
SAN DIEGO, CA / ACCESSWIRE / May 7, 2019 / Calidi Biotherapeutics, Inc. is happy to announce the United States Patent Office has granted Calidi Biotherapeutics a patent for cell-based delivery of ...
- FDA Panel Gives Thumbs-Up To Amgen’s Virus-Based Melanoma Drugon April 28, 2019 at 5:00 pm
T-VEC is made from a modified herpes bug and would likely be the first among a number of virus-based cancer treatments in the pharma pipeline to be approved. Of the 23 members on the panel, all but ...
- Virus-based therapy to target eye canceron January 26, 2019 at 4:02 pm
A cancer-killing, virus-based therapy developed in Spain has shown some promise against retinoblastoma (which is a tumour of the retina that affects mainly children) in mouse models and a pilot ...
- Pediatric Eye Cancer Could be Treated With Virus-Based Therapyon January 24, 2019 at 4:38 am
Retinoblastoma, an eye cancer affecting the retina, most predominantly occurs in the children. A cancer-killing, virus-based therapy showed promising effects against cancer in a pilot clinical trial ...
- Virus-based therapy targets a pediatric eye canceron January 23, 2019 at 11:05 am
A cancer-killing, virus-based therapy showed promising effects against retinoblastoma - a tumor of the retina that affects mainly children - in mouse models and a pilot clinical trial. Although ...
- PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumorson November 15, 2018 at 10:54 am
and the Parker Institute for Cancer Immunotherapy (Parker Institute) today announced a research project to investigate the use of PsiOxus' virus-based gene therapy for treating solid tumors that have ...
- Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruseson October 25, 2018 at 2:10 am
Patent Number: 10,105,436 "Smallpox Vaccine for Cancer Treatment" covers the use of oncolytic ... that stem cells will provide a superior delivery system for oncolytic virus-based therapies both now ...
via Bing News